TotalMarketCap

Repligen

RGENNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$9.271 B

$189.50 +4.29%

Close of 6 Oct 2026

As of 6 Oct 2026, Repligen (RGEN) has a market capitalization of $9.27B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

$48.9M

#1578 by earnings

Shares outstanding

56,435,621

Latest filing cover page

P/E ratio

189.6

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →
  1. #15Krystal BiotechKRYS$9.91B
  2. #16QiagenQGEN$9.44B
  3. #17RepligenRGEN$9.27B
  4. #18Kymera TherapeuticsKYMR$9.13B
  5. #19ImmunovantIMVT$6.87B

What if Repligen were worth as much as…

Open the what-if tool →

Gold $28.8T

$589,307.96

Per share 3,110× higher

Bitcoin $1.68T

$34,402.88

Per share 182× higher

Nvidia $5.76T

$117,683.93

Per share 621× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for Repligen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 7 Oct 2026. Read the methodology.